ELVHealthcare · Healthcare PlansThe 22 Wall Street analysts covering Elevance Health, Inc. hold a median 12-month price target of $492 — +13.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Elevance Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (94): The share count has been shrinking and the company is not leaning on new borrowing.
Accruals (40): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ELV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +13.2% from it.
Of the 20 most recent actions, 13 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | Wells Fargo | Maintains | Overweight | $473 → $492 |
| 23 Oct 2026 | TD Cowen | Maintains | Buy | $465 → $495 |
| 22 Oct 2026 | Baird | Maintains | Neutral | $393 → $406 |
| 22 Oct 2026 | Barclays | Maintains | Overweight | $469 → $472 |
| 22 Oct 2026 | Guggenheim | Maintains | Buy | $460 → $485 |
| 22 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | $404 → $449 |
| 22 Oct 2026 | RBC Capital | Maintains | Sector Perform | $424 → $455 |
| 22 Oct 2026 | UBS | Maintains | Buy | $460 → $523 |
| 12 Oct 2026 | Guggenheim | Maintains | Buy | — |
| 12 Oct 2026 | Guggenheim | Maintains | Buy | $455 → $460 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | — |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $457 → $469 |
| 17 July 2026 | Bernstein | Maintains | Outperform | — |
| 17 July 2026 | Bernstein | Maintains | Outperform | $482 → $488 |
| 17 July 2026 | Leerink Partners | Maintains | Market Perform | — |
| 17 July 2026 | Leerink Partners | Maintains | Market Perform | $364 → $395 |
| 16 July 2026 | Baird | Maintains | Neutral | $331 → $393 |
| 16 July 2026 | Baird | Maintains | Neutral | — |
| 16 July 2026 | Barclays | Maintains | Overweight | $480 → $457 |
| 16 July 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ELV appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Elevance Health, Inc. returned +40.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 41% of US stocks
Cheaper than 83% of US stocks
Cheaper than 43% of US stocks
Cheaper than 39% of US stocks
Higher than 31% of US stocks
Higher than 54% of US stocks
Higher than 53% of US stocks
Higher than 53% of US stocks
Higher than 67% of US stocks
Higher than 71% of US stocks
Higher than 76% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Elevance Health, Inc. has a market value of $89.7B and an enterprise value of $82.4B.
Revenue in the twelve months to 30 June 2026: $201.1B. The latest quarter grew 1.4% year on year.
Net income over the same four quarters: $4.9B, a 2.5% net margin.
Diluted earnings per share, trailing twelve months: $22.50.
Free cash flow in the twelve months to 30 June 2026: $6.3B, after $1.2B of capital spending.
Elevance Health, Inc. spent $2.7B on share buybacks and $1.5B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 17.6×; forward P/E: 13.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.66%, paying out 29% of earnings.
Elevance Health, Inc. employs 96,129 people — $2.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Elevance Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CVS Health shares fell 12% after the company announced a plan to split into two companies, despite a strong quarter. Elevance Health shares rose 4%, while Cigna shares climbed 3%.
Why it matters — The report notes a gain in Elevance shares alongside the market reaction to CVS’s proposed breakup.
The headline reports that Elevance Health (ELV) is up 2.73% over one week. The excerpt poses a question about whether the stock may appeal to momentum investors but provides no further analysis.
Why it matters — ELV watchers may note the reported one-week gain and the article’s focus on momentum investing.
Zacks Investment Research reports that implied volatility for Elevance Health stock options is surging, citing recent movements in the options market.
Why it matters — ELV watchers may find the options-market activity relevant when following investor expectations and trading in the stock.
Zacks Investment Research compares Elevance Health and Revvity as potential value stocks in the Medical Services sector, asking which offers value investors better value.
Why it matters — The item puts ELV in a side-by-side value comparison with Revvity but provides no conclusion in the excerpt.
Elevance Health raised its 2026 adjusted EPS guidance to at least $29, and third-quarter adjusted EPS increased 15.9%. However, nine-month operating gain declined 25.7%, and Health Benefits margins remain under pressure, especially in Medicaid.
Why it matters — Investors tracking ELV may weigh stronger quarterly earnings and improved medical cost trends against questions about the sustainability of its recovery and continued margin pressure.
The 22 Wall Street analysts covering Elevance Health, Inc. have a median 12-month price target of $492, with estimates ranging from $406 to $523. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 22 analysts covering Elevance Health, Inc., 15 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elevance Health, Inc. 77 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Elevance Health, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (94 of 100).
No one can know that. What the data says: the median 12-month target from 22 analysts implies +13.2% from the last close, and Ticker Nerd's factor model ranks Elevance Health, Inc. 77 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Elevance Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $406 to $523 over the next 12 months.
Elevance Health, Inc. returned +40.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Elevance Health, Inc. is a U.S.
The most recent item we track (24/7 Wall Street, 4 Nov 2026): "CVS Tumbles 12% on Plan to Split Into Two Companies Despite Earnings Beat; Elevance Health Rises 4%, Cigna Climbs 3%". CVS Health shares fell 12% after the company announced a plan to split into two companies, despite a strong quarter. Elevance Health shares rose 4%, while Cigna shares climbed 3%.
Elevance Health, Inc. is a U.S. health benefits and health services company headquartered in Indianapolis, Indiana. It provides a broad range of health insurance products and related services for individuals, employers, and government-sponsored programs, with offerings that include commercial medical coverage, Medicare and Medicaid plans, dental, vision, behavioral health, and pharmacy benefits. The company operates through Health Benefits, CarelonRx, Carelon Services, and Corporate & Other, combining insurance operations with care management and healthcare enablement services. Elevance Health serves as a major participant in managed care, helping coordinate medical coverage, administrative services, and integrated care solutions across the U.S. healthcare system. Its portfolio is designed to support members, providers, and employer groups through a whole-health approach that links benefits, clinical support, and pharmacy services.
CEO Ms. Gail Koziara Boudreaux · 96,129 employees · United States · https://www.elevancehealth.com
